Oncology

Overview

The Oncology research area is composed by nine groups addressing the principal unsolved issues in cancer. Their research covers fields such as child and adolescent cancer, melanoma, Gynecology, Urology, cancer stem cells and the molecular mechanisms of the tumor pathologies.

There are also three groups from the CIBBIM-Nanomedicine. These groups study the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics.

Publications

120

total

757.123

impact factor

6.309

average impact factor

Director: Joan Morote Robles

team

zoom

download

Our Group is formed by Urologists, Pathologists and Specialists in Biology dedicated to basic and translational research in urological diseases, mainly prostate cancer (PCa) and kidney cancer. Since its inception, the Group’s doctors and basic researchers have maintained a close collaboration and share a common interest in the understanding the causes of cancer development and progression. This collaboration allows the identification of unresolved problems in clinical practice and their translation to the research laboratory, where the team of experienced basic scientists applies the most effective strategies to investigate and solve critical problems.

17

total

166^.348

impact factor

9^.785

average impact factor

SELECTED ARTICLES

Sequeiros T; Rigau M; Chiva C; Montes M; Garcia-Grau I; Garcia M; Diaz S; Celma A; Bijnsdorp I; Campos A; DiMauro P; Borrós S; Reventós J; Paciucci R; Pegtel M; deTorres I; Sabidó E; Morote J; Olivan M.
Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. Oncotarget,
2017; 8(3):4960-4976.
IF 5,168 Oncology Q=1.

Vilardell J, Alcaraz E, Sarró E, Trilla E, Cuadros T, de Torres I, Plana M, Ramón Y Cajal S, Pinna LA, Ruzzene M, Morote J, Meseguer A, Itarte E.
Under-expression of CK2? subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival. Oncotarget.
2017;9(5):5736-5751.
doi: 10.18632/oncotarget.23422.
IF 5,168 Oncology Q=1.

Caro-Maldonado A, Camacho L, Zabala-Letona A, Torrano V, Fernández-Ruiz S, Zamacola-Bascaran K, Arreal L, Valcárcel-Jiménez L, Martín-Martín N, Flores JM, Cortazar AR, Zúñiga-García P, Arruabarrena-Aristorena A, Guillaumond F, CabreraD, Falcón-Perez JM, Aransay AM, Gomez-Muñoz A, Olivan M, Morote J, Carracedo A.
Low-dose statin treatment increases prostate cancer aggressiveness. Oncotarget.
2017;9(2):1494-1504.
doi: 10.18632/oncotarget.22217.
IF 5,168 Oncology Q=1.

Morote J, Comas I, Ferrer R, Planas J, Celma A, Regis L.
Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients. J Biomed Sci.
2017;24(1):81.
doi: 10.1186/s12929-017-0386-0.
IF:2,799 Oncology.

Cánovas V, Puñal Y, Maggio V, Redondo E, Marín M, Mellado B, Olivan M, Lleonart M, Planas J, Morote J, Paciucci R.
Prostate Tumor Overexpressed-1(PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells. Oncotarget.
2017;8(35):59165-59180.
doi:10.18632/oncotarget.19467.
IF 5,168 Oncology Q=1.

View all publications

Oncology

Overview

Publications

Director: Joan Morote Robles

Research Areas